Fig 1.
COVID-19, coronavirus disease 2019; ARDS, acute respiratory distress syndrome; HFNC, high-flow nasal cannula.
Table 1.
Baseline characteristics of patients with COVID-19 associated ARDS who commenced HFNC therapy.
Fig 2.
Daily ROX index values between patients in the HFNC failure group and those in the HFNC success group.
HFNC, high-flow nasal cannula; ROX, respiratory rate-oxygenation.
Fig 3.
The discriminative ability of ROX index, SpO2/FiO2, FiO2, RR, and SpO2 in determining HFNC failure.
HFNC, high-flow nasal cannula; ROX, respiratory rate-oxygenation; RR, respiratory rate.
Table 2.
Diagnostic performance of ROX index cut-offs in determining HFNC failure.
Table 3.
Diagnostic performance of the ROX index compared with that of other respiratory parameters in determining HFNC failure.